Clinical Trial Update: A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer [Phase 4]

View source ↗

Summary

A Phase 4 trial of abemaciclib in HR+, HER2- advanced/metastatic breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metastatic Breast Cancer | Phase 4 | Status: WITHDRAWN